{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T22:46:00Z","timestamp":1795041960050,"version":"4.10.2"},"reference-count":40,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004391","name":"China Medical University Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004391","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014476","name":"Pfizer Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014476","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.ijantimicag.2023.107072","type":"journal-article","created":{"date-parts":[[2023,12,26]],"date-time":"2023-12-26T21:38:37Z","timestamp":1703626717000},"page":"107072","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Global trends in non-susceptibility rates of Streptococcus pneumoniae isolates to ceftriaxone: Data from the antimicrobial testing leadership and surveillance (ATLAS) programme, 2016\u201321"],"prefix":"10.1016","volume":"63","author":[{"given":"Jiun-Ling","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chih-Cheng","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Chien","family":"Ko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Po-Ren","family":"Hsueh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2023.107072_bib0001","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1164\/rccm.201908-1581ST","article-title":"Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America","volume":"200","author":"Metlay","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ijantimicag.2023.107072_bib0002","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.jmii.2018.11.004","article-title":"Recommendations and guidelines for the treatment of pneumonia in Taiwan","volume":"52","author":"Chou","year":"2019","journal-title":"J Microbiol Immunol Infect"},{"key":"10.1016\/j.ijantimicag.2023.107072_bib0003","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/S0140-6736(21)00630-9","article-title":"Community-acquired pneumonia","volume":"398","author":"Aliberti","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.ijantimicag.2023.107072_bib0004","doi-asserted-by":"crossref","first-page":"i8","DOI":"10.1093\/jac\/dkad065","article-title":"Antimicrobial susceptibility testing of invasive isolates of Streptococcus pneumoniae from Canadian patients: the SAVE study, 2011\u20132020","volume":"78","author":"Alford","year":"2023","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2023.107072_bib0005","doi-asserted-by":"crossref","first-page":"e744","DOI":"10.1016\/S2666-5247(22)00127-6","article-title":"Effect of pneumococcal conjugate vaccines and SARS-CoV-2 on antimicrobial resistance and the emergence of Streptococcus pneumoniae serotypes with reduced susceptibility in Spain, 2004\u201320: a national surveillance study","volume":"3","author":"Sempere","year":"2022","journal-title":"Lancet Microbe"},{"key":"10.1016\/j.ijantimicag.2023.107072_bib0006","doi-asserted-by":"crossref","first-page":"ofad098","DOI":"10.1093\/ofid\/ofad098","article-title":"Trends in Streptococcus pneumoniae antimicrobial resistance in US children: a multicenter evaluation","volume":"10","author":"Mohanty","year":"2023","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.107072_bib0007","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1016\/j.jmii.2020.01.003","article-title":"The antimicrobial susceptibility in adult invasive pneumococcal disease in the era of pneumococcus vaccination: a hospital-based observational study in Taiwan","volume":"53","author":"Lee","year":"2020","journal-title":"J Microbiol Immunol Infect"},{"key":"10.1016\/j.ijantimicag.2023.107072_bib0008","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.jmii.2021.05.008","article-title":"Nationwide surveillance of antimicrobial resistance in invasive isolates of Streptococcus pneumoniae in Taiwan from 2017 to 2019","volume":"55","author":"Tsai","year":"2022","journal-title":"J Microbiol Immunol Infect"},{"key":"10.1016\/j.ijantimicag.2023.107072_bib0009","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1111\/j.1469-0691.2010.03182.x","article-title":"Changes in antimicrobial resistance, serotypes and genotypes in Streptococcus pneumoniae over a 30-year period","volume":"16","author":"Li\u00f1ares","year":"2010","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijantimicag.2023.107072_bib0010","doi-asserted-by":"crossref","first-page":"e361","DOI":"10.1097\/MJT.0000000000000551","article-title":"Antimicrobial resistant Streptococcus pneumoniae: prevalence, mechanisms, and clinical implications","volume":"24","author":"Cherazard","year":"2017","journal-title":"Am J Ther"},{"key":"10.1016\/j.ijantimicag.2023.107072_bib0011","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1086\/322623","article-title":"Clinical outcomes of bacteremic pneumococcal pneumonia in the era of antibiotic resistance","volume":"33","author":"Moroney","year":"2001","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.107072_bib0012","doi-asserted-by":"crossref","first-page":"3293","DOI":"10.1128\/AAC.02580-13","article-title":"Factors associated with ceftriaxone nonsusceptibility of Streptococcus pneumoniae: analysis of South African national surveillance data, 2003 to 2010","volume":"58","author":"von Mollendorf","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2023.107072_bib0013","doi-asserted-by":"crossref","first-page":"4650","DOI":"10.1128\/AAC.00239-12","article-title":"Impact of penicillin nonsusceptibility on clinical outcomes of patients with nonmeningeal Streptococcus pneumoniae bacteremia in the era of the 2008 Clinical and Laboratory Standards Institute Penicillin breakpoints","volume":"56","author":"Choi","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2023.107072_bib0014","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.jmii.2016.12.004","article-title":"Invasive pneumococcal disease caused by ceftriaxone-resistant Streptococcus pneumoniae in Taiwan","volume":"51","author":"Lee","year":"2018","journal-title":"J Microbiol Immunol Infect"},{"key":"10.1016\/j.ijantimicag.2023.107072_bib0015","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1128\/AAC.06185-11","article-title":"Evaluation of ceftaroline activity versus ceftriaxone against clinical isolates of Streptococcus pneumoniae with various susceptibilities to cephalosporins in an in vitro pharmacokinetic\/pharmacodynamic model","volume":"56","author":"Steed","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl 3","key":"10.1016\/j.ijantimicag.2023.107072_bib0016","doi-asserted-by":"crossref","first-page":"S206","DOI":"10.1093\/cid\/cis563","article-title":"In vitro activity of ceftaroline against multidrug-resistant Staphylococcus aureus and Streptococcus pneumoniae: a review of published studies and the AWARE Surveillance Program (2008\u20132010)","volume":"55","author":"Farrell","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.107072_bib0017","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1056\/NEJMoa1401914","article-title":"Effects of vaccination on invasive pneumococcal disease in South Africa","volume":"371","author":"von Gottberg","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijantimicag.2023.107072_bib0018","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1111\/apa.15795","article-title":"Multi-drug resistance in Streptococcus pneumoniae among children in rural Vietnam more than doubled from 1999 to 2014","volume":"110","author":"Larsson","year":"2021","journal-title":"Acta Paediatr"},{"key":"10.1016\/j.ijantimicag.2023.107072_bib0019","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/j.jmii.2019.04.006","article-title":"The clinical implication of serotype distribution and drug resistance of invasive pneumococcal disease in children: a single center study in southern Taiwan during 2010\u20132016","volume":"52","author":"Lee","year":"2019","journal-title":"J Microbiol Immunol Infect"},{"key":"10.1016\/j.ijantimicag.2023.107072_bib0020","article-title":"Spread of ceftriaxone non-susceptible pneumococci in South Korea: long-term care facilities as a potential reservoir","volume":"14","author":"Choi","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.ijantimicag.2023.107072_bib0021","series-title":"Performance standards for antimicrobial susceptibility testing","year":"2021"},{"key":"10.1016\/j.ijantimicag.2023.107072_bib0022","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1093\/ofid\/ofy263","article-title":"Antimicrobial susceptibility of Streptococcus pneumoniae from North America, Europe, Latin America, and the Asia\u2013Pacific region: results from 20 years of the SENTRY antimicrobial surveillance program (1997\u20132016)","volume":"6","author":"Sader","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.107072_bib0023","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1093\/cid\/ciz739","article-title":"Early impact of 13-valent pneumococcal conjugate vaccine use on invasive pneumococcal disease among adults with and without underlying medical conditions \u2013 United States","volume":"70","author":"Ahmed","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.107072_bib0024","doi-asserted-by":"crossref","first-page":"e3778","DOI":"10.1093\/cid\/ciaa1483","article-title":"Nationwide trends of invasive pneumococcal disease in Spain from 2009 through 2019 in children and adults during the pneumococcal conjugate vaccine era","volume":"73","author":"de Miguel","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.107072_bib0025","doi-asserted-by":"crossref","first-page":"3111","DOI":"10.1016\/j.vaccine.2023.04.023","article-title":"Prevalence, capsular types, antimicrobial resistance and risk factors associated with pneumococcal carriage among children after long-term 10-valent pneumococcal conjugate vaccine use in Brazil","volume":"41","author":"Fortuna","year":"2023","journal-title":"Vaccine"},{"key":"10.1016\/j.ijantimicag.2023.107072_bib0026","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1128\/AAC.05658-11","article-title":"Changing trends in antimicrobial resistance and serotypes of Streptococcus pneumoniae isolates in Asian countries: an Asian Network for Surveillance of Resistant Pathogens (ANSORP) study","volume":"56","author":"Kim","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2023.107072_bib0027","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1586\/17476348.2013.816572","article-title":"Advances in pneumococcal antibiotic resistance","volume":"7","author":"Song","year":"2013","journal-title":"Expert Rev Respir Med"},{"key":"10.1016\/j.ijantimicag.2023.107072_bib0028","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1080\/21645515.2018.1470726","article-title":"Current status and future directions of invasive pneumococcal diseases and prophylactic approaches to control them","volume":"14","author":"Wantuch","year":"2018","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.ijantimicag.2023.107072_bib0029","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003733","article-title":"Levels of pneumococcal conjugate vaccine coverage and indirect protection against invasive pneumococcal disease and pneumonia hospitalisations in Australia: an observational study","volume":"18","author":"Chan","year":"2021","journal-title":"PLoS Med"},{"key":"10.1016\/j.ijantimicag.2023.107072_bib0030","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1136\/thoraxjnl-2018-211767","article-title":"Effect of childhood pneumococcal conjugate vaccination on invasive disease in older adults of 10 European countries: implications for adult vaccination","volume":"74","author":"Hanquet","year":"2019","journal-title":"Thorax"},{"key":"10.1016\/j.ijantimicag.2023.107072_bib0031","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/14760584.2017.1334555","article-title":"Pneumococcal conjugate vaccines in Latin America: are PCV10 and PCV13 similar in terms of protection against serotype 19A?","volume":"16","author":"Avila-Aguero","year":"2017","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.ijantimicag.2023.107072_bib0032","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1586\/14760584.2016.1166961","article-title":"Pneumococcal conjugate vaccine introduction in Latin America and the Caribbean: progress and lessons learned","volume":"15","author":"de Oliveira","year":"2016","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.ijantimicag.2023.107072_bib0033","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.jmii.2022.08.018","article-title":"Antimicrobial susceptibility and serotype replacement of Streptococcus pneumoniae in children before and after PCV13 introduction in Taiwan","volume":"56","author":"Huang","year":"2023","journal-title":"J Microbiol Immunol Infect"},{"key":"10.1016\/j.ijantimicag.2023.107072_bib0034","doi-asserted-by":"crossref","first-page":"257","DOI":"10.3947\/ic.2016.48.4.257","article-title":"Indirect effects of pneumococcal conjugate vaccines in national immunization programs for children on adult pneumococcal disease","volume":"48","author":"Kim","year":"2016","journal-title":"Infect Chemother"},{"key":"10.1016\/j.ijantimicag.2023.107072_bib0035","doi-asserted-by":"crossref","first-page":"379","DOI":"10.46234\/ccdcw2023.072","article-title":"Coverage of 13-valent pneumococcal conjugate vaccine among children 0\u201315 months of age \u2013 9 provinces, China, 2019\u20132021","volume":"5","author":"Liu","year":"2023","journal-title":"China CDC Wkly"},{"key":"10.1016\/j.ijantimicag.2023.107072_bib0036","doi-asserted-by":"crossref","first-page":"742","DOI":"10.3390\/microorganisms9040742","article-title":"Global landscape review of serotype-specific invasive pneumococcal disease surveillance among countries using PCV10\/13: the pneumococcal serotype replacement and distribution estimation (PSERENADE) project","volume":"9","author":"Deloria Knoll","year":"2021","journal-title":"Microorganisms"},{"key":"10.1016\/j.ijantimicag.2023.107072_bib0037","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.jmii.2023.01.013","article-title":"Microbiological and clinical characteristics of Streptococcus pneumoniae serotype 3 infection and risk factors for severe outcome: a multicenter observational study","volume":"56","author":"Aydin","year":"2023","journal-title":"J Microbiol Immunol Infect"},{"key":"10.1016\/j.ijantimicag.2023.107072_bib0038","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1093\/jac\/46.5.767","article-title":"Streptococcus pneumoniae resistance to erythromycin and penicillin in relation to macrolide and beta-lactam consumption in Spain (1979\u20131997)","volume":"46","author":"Granizo","year":"2000","journal-title":"J Antimicrob Chemother"},{"issue":"Suppl 3","key":"10.1016\/j.ijantimicag.2023.107072_bib0039","first-page":"iii19","article-title":"FOCUS 1: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia","volume":"66","author":"File","year":"2011","journal-title":"J Antimicrob Chemother"},{"issue":"Suppl 3","key":"10.1016\/j.ijantimicag.2023.107072_bib0040","doi-asserted-by":"crossref","first-page":"iii33","DOI":"10.1093\/jac\/dkr097","article-title":"FOCUS 2: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia","volume":"66","author":"Low","year":"2011","journal-title":"J Antimicrob Chemother"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857923003618?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857923003618?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T17:45:58Z","timestamp":1760377558000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857923003618"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":40,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["S0924857923003618"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2023.107072","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Global trends in non-susceptibility rates of Streptococcus pneumoniae isolates to ceftriaxone: Data from the antimicrobial testing leadership and surveillance (ATLAS) programme, 2016\u201321","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2023.107072","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd and International Society of Antimicrobial Chemotherapy. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"107072"}}